# Sai Life Sciences share price today (Sai Life Sciences Ltd, NSE: SAILIFE)

> Sai Life Sciences share price today: ₹1,546.10 at the NSE close on 4 November 2026, up 76.6% in a year. Sai Life Sciences (NSE: SAILIFE) is worth ₹32,840 crore, trades at a P/E of 89.3 and has closed between ₹795.00 and ₹1,600.50 over the past 52 weeks. > Sai Life Sciences Ltd's earnings have grown faster than its share price. Earnings per share grew +102.0% in a year while the price moved +76.6%. SAILIFE · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/sai-life-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹1,546.10 (+76.6% in a year)
- P/E: 89.3× (higher than 77% of the last 1 year)
- Revenue (Jun 2026): ₹554 Cr (+11.7% on a year ago)
- Profit (Jun 2026): ₹73.0 Cr (+21.7% on a year ago)
- Operating margin: 27.0% (+3.0 points on a year ago)
- ROCE: 20%, FY26
- ROIC: 14.0%, against a 12.0% cost of capital: +2.0 points
- Profit that came in as cash: 180%, last 3 years

The main question: yearly earnings per share moved +102.0% while the share price moved +76.6%. ## What is the Sai Life Sciences share price today? Sai Life Sciences Ltd's share price was ₹1,546.10 at the close on 4 November 2026. It has been rising for 70 weeks. That is 23.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹795 and ₹1,601, and at that close it sat 93% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 46 weeks in a row. Over the last 1 year the share price moved +120% while the NIFTY 500 moved −2%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sai Life Sciences this quarter? Three changes stood out: promoters cut their stake for 7 quarters in a row, revenue up on a year earlier for 7 quarters in a row (every quarter we can compare) and profit up on a year earlier for 7 quarters in a row (every quarter we can compare). 1. Promoters cut their stake for 7 quarters in a row From 35.2% to 34.5% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 7 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹554 crore, +11.7% on a year earlier. Why: Revenue rose because both parts of the business grew, and the discovery capacity filled up quickly. Next results: check whether shipment timing and new capacity make the second half stronger than the first. From the earnings call on 7 Aug 2026. 3. Profit up on a year earlier for 7 quarters in a row (every quarter we can compare) In the June 2026 quarter profit was ₹73 crore, +21.7% on a year earlier. ## What are Sai Life Sciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Sai Life Sciences reported revenue of ₹554 crore, up 11.7% from ₹496 crore a year earlier, and a profit of ₹73.0 crore, up 21.7% from ₹60.0 crore. ### Sai Life Sciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹554 crore | ₹496 crore | +11.7% |
| Profit | ₹73.0 crore | ₹60.0 crore | +21.7% |
| Earnings per share | ₹3.45 | ₹2.90 | +19.0% |
| Operating margin | 27.0% | 24.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sai Life Sciences' management discussed these results on a call held on 7 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Sai Life Sciences share price history? Sai Life Sciences closed at ₹1,546.10 on 4 November 2026, up 76.6% from ₹875.45 a year earlier (7 November 2025). Its highest weekly close since December 2024 was ₹1,600.50 on 18 September 2026. ### Sai Life Sciences share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹1,557.50 | −0.7% |
| 1 month ago · 1 Oct 2026 | ₹1,541.20 | +0.3% |
| 6 months ago · 8 May 2026 | ₹1,115.60 | +38.6% |
| 1 year ago · 7 Nov 2025 | ₹875.45 | +76.6% |
| Earliest weekly close in our records · 20 Dec 2024 | ₹703.65 | +119.7% |
| Highest weekly close since December 2024, also the 52-week high · 18 Sep 2026 | ₹1,600.50 | −3.4% |
| Lowest weekly close since December 2024 · 1 Feb 2025 | ₹655.40 | +135.9% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹795.00 | +94.5% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (106 weekly closes from 20 December 2024 to 4 November 2026.)

## What is the latest news on Sai Life Sciences? 4 Nov 2026: Sai Life Sciences closed at ₹1,546.10, down 0.7% on the week and up 0.3% on the month. 7 Aug 2026: Sai Life Sciences held its results call for April to June 2026. Management guided: Revenue growth of 15-20% over 3-5 years. ### Earlier

- Results for April to June 2026: Revenue up 11.7% and profit up 21.7% on a year earlier. ## What dividend does Sai Life Sciences pay? Sai Life Sciences has paid no dividend on the NSE since its first NSE close in our records (20 December 2024), the start of the period we checked. Not in its latest year. Sai Life Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 2 of its last 8 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Sai Life Sciences management say on the latest results call? On the call for April to June 2026, held on 7 August 2026, Sai Life Sciences' management guided: Revenue growth of 15-20% over 3-5 years. > “We believe the biggest long-term opportunity is to continue building a fully integrated delivery engine, from discovery through commercial manufacturing.”
> Krishna Kanumuri, MD & CEO, on the call for April to June 2026

### What management guided

- Operating profit range of 28-30% sustained over the longer term. - FY27 capital spending ₹1,100-1,300 crore remains unchanged. - H2 FY27 stronger than H1; total manufacturing capacity planned at 1,150 KL by FY27, with the 450 KL Bidar expansion first block in H2/Q3 and second by FY27-end. - At least two large pharma customers planned for integrated services this year; another FTE engagement expected to close by end-Q2 and start in Q3; two further Phase 3 milestones expected this year and another in July to September 2027. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/58208/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 7 August 2026.)

## What is the future of Sai Life Sciences? What is changing in the business? What is changing at Sai Life Sciences, from the latest results and calls: integrated customer programmes, bidar capacity commissioning and discovery capacity and cro conversion. - Integrated customer programmes. Integrated services and FTE relationships can move work from discovery into development and commercial manufacturing. ⚠ estimate
- Bidar capacity commissioning. The first manufacturing block is expected in H2 FY27 and the second is planned by FY27-end; this is the near-term test of capacity-led revenue delivery. ⚠ estimate
- Discovery capacity and CRO conversion. New discovery capacity was reported fully booked, supporting customer expansion into integrated CRO work. ⚠ estimate
- Late-stage and commercial pipeline. The disclosed CMC pipeline and regulatory milestones provide a route to future commercial manufacturing work. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 22 August 2026.)

## What could change the Sai Life Sciences story? What are the risks? The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. ### Each change stops working if

- Integrated customer programmes: Customers retain discovery work but shift development or commercial work to other suppliers. - Bidar capacity commissioning: Commissioning slips beyond the stated FY27 windows or capacity opens without customer utilization. - Discovery capacity and CRO conversion: Discovery demand normalizes before integrated programmes enter later development stages. - Late-stage and commercial pipeline: Late-stage regulatory milestones slip or customers do not award commercial supply. ### The main risks

- Capacity execution and return dilution: A large spending programme can depress cash generation and asset turns before revenue catches up. ✓ fact
- Margin normalization: April to June 2026 operating margin was below the preceding quarter and management guides a sustained band rather than further expansion. ⚠ estimate
- Customer concentration: The prior call comparison recorded higher top-customer concentration, creating exposure to programme timing at a small set of customers. ✓ fact

(Our read after the latest results, written 22 August 2026.)

## What to watch in Sai Life Sciences' next results? When Sai Life Sciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Bidar production-block commissioning - check schedule slippage and early utilisation when the new capacity comes online. - What to check (from the call)
- Bidar production-block commissioning - check schedule slippage and early utilisation when the new capacity comes online. - H2 delivery cadence - check whether shipment timing and capacity availability produce the stronger second-half outcome described on the call. - FTE conversion and regulatory progress - check additional integrated programs and milestones across the disclosed late-stage pipeline. - Peptide, ADC and formulation readiness - check commissioning and first customer-validation activity across the new platforms. ## Which stock lists is Sai Life Sciences on? Sai Life Sciences is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks. - [Momentum stocks Market cap cr: 32850.77836276083](https://www.sectoralpha.in/momentum-stocks-india)
- [Small & mid cap stocks Size rank in India: 254](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 32850.77836276083](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Sai Life Sciences profitable? Sai Life Sciences Ltd earned ₹73.0 Cr of net profit in the Jun 2026 quarter, +21.7% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹349 Cr. Over 7 years profit has grown 25.0% a year on average. That is 13.2% of the quarter's revenue. The same quarter a year earlier earned ₹60.0 Cr. 1 of the last 11 reported quarters were loss-making. For the full year, FY26 profit was ₹349 Cr (+105.3% on the year before). Why profit moved: revenue changed +11.7% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +56.3% and revenue +19.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sai Life Sciences make, and is it growing? Sai Life Sciences Ltd reported ₹554 Cr of revenue in the Jun 2026 quarter, +11.7% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 7 years it has grown 17.8% a year on average. The last full year, FY26, came in at ₹2,192 Cr. Why this happened. The capex inflection point can extend growth once capacity is commissioned and utilized. The May timetable placed the remaining 225 KL in FY28, whereas the August call goals the second block by FY27-end. The current schedule must therefore be treated as a monitored trigger rather than delivered capacity. The last four reported quarters add to ₹2,249 Cr. FY26 revenue was ₹2,192 Cr, +29.3% on the year before. Recent pace: the last four quarters grew +19.4% on average, against 17.8% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Sai Life Sciences keep? Sai Life Sciences Ltd's operating margin was 27.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 8 years it has been between 14.0% and 29.0%. The latest quarter is within that range. Why this happened. Management says integrated services cover many customers and cites a customer relationship that expanded into an end-to-end programme. This is the value-chain climb: revenue durability improves only if those programmes convert through later stages. Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +2.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Sai Life Sciences' profit turning into cash? Over the last 3 years, 180% of Sai Life Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹509 Cr of operating cash against ₹349 Cr of profit. After ₹640 Cr of spending on assets, free cash was −₹131 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 180% of profit came in as cash: the cash cycle got 20 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building. ## Where does Sai Life Sciences' cash go? Sai Life Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −24 days in FY26, down from −4 days in FY21. It spent ₹1,322 Cr on assets over the last 3 years. Customers take 62 days to pay, and stock sits for 97 days on average. At FY26 sales of ₹2,192 Cr, each day of that cycle ties up about ₹6.0 Cr, so roughly −₹144 Cr is tied up in the business at any time. FY26: customers took 62 days to pay and stock sat for 97 days, about 3.2 months of sales sitting as stock, for a full cycle of −24 days, shorter than FY21's −4. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 97 days. Customers pay about 62 days after that. Suppliers are paid at 182 days. Together that makes the −24-day cycle. Spending on assets: ₹1,322 Cr over the last 3 years, against ₹425 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹270 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sai Life Sciences' P/E ratio, and how does it compare with its own history? Sai Life Sciences Ltd's P/E is 89.3×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 67.7×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹17.12. Why the multiple is where it is: over the past year earnings per share moved +102.0% while the price moved +76.6%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sai Life Sciences business getting better or worse? Sai Life Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Sai Life Sciences story, and has it been checked? Sai Life Sciences Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: PEAK. Still open: The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. Our read, 22 August 2026. From the numbers. The normalized-margin…

From the price. Price stage 2, week 70, above its 200-day line, relative strength falling. From the research. Where they disagree. What is proven. What is not proven yet. The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. What would change our mind. The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. The test written in advance. The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. Measured by: the thesis as written as stated by the next result. The test written in advance. The test written in advance. Capacity execution and return dilution. Measured by: Capacity execution and return dilution Bidar blocks commissioned within the stated FY27 windows and capacity utilization disclosure by the next result. What the company does. Q1 FY27 revenue and PAT rose year on year while operating margin fell from the preceding quarter, showing growth without a fresh margin step-up. What the surface reading misses. What the surface reading misses. The surface reading is: A 26.7% operating margin looks close to normalized profitability. The research reads it further: The normalized margin is only modestly above current margin, while normalized non-operating and earnings adjustments lower EPS. Lever 1 · Operating leverage: building. Integrated services and FTE relationships can move work from discovery into development and commercial manufacturing. What proves it keeps working: Integrated customer programmes. It stops working if Customers retain discovery work but shift development or commercial work to other suppliers. Lever 6 · Order-book wins: building. The first manufacturing block is expected in H2 FY27 and the second is planned by FY27-end; this is the near-term test of capacity-led revenue delivery. What proves it keeps working: Bidar capacity commissioning. It stops working if Commissioning slips beyond the stated FY27 windows or capacity opens without customer utilization. Lever 14 · A bigger market to serve: building. New discovery capacity was reported fully booked, supporting customer expansion into integrated CRO work. What proves it keeps working: Discovery capacity and CRO conversion. It stops working if Discovery demand normalizes before integrated programmes enter later development stages. Lever 2 · Value-added mix: building. The disclosed CMC pipeline and regulatory milestones provide a route to future commercial manufacturing work. What proves it keeps working: Late-stage and commercial pipeline. It stops working if Late-stage regulatory milestones slip or customers do not award commercial supply. Sources: our stock research file (22 August 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Sai Life Sciences management deliver what it promised? What Sai Life Sciences Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Capacity Expansion Timeline Delayed · 15 May 2026. Both the Aug 2025 and Nov 2025 calls explicitly committed to completing the full 450 KL capacity addition, bringing total installed capacity to approximately 1,150 KL, by the second half of FY27 or by end of FY27 at the latest. The May 2026 call discloses that only 225 KL will come online in FY27 with the remaining 225 KL pushed to FY28, a one-year delay for half the planned new capacity that management did not specifically address or explain. Customer Concentration Rose Sharply · 15 May 2026. The Aug 2025 call disclosed top 10 customer concentration at approximately 40% based on the most recent full year data, with management across prior calls framing diversification and management of concentration as a core risk priority. The May 2026 call reveals top 10 customer concentration jumped to 54% in FY26, a 14 percentage point increase in a single year, which is inconsistent with the diversification narrative and was presented without a specific explanation for the increase. Strategic Pivot Disclosed as Product Failure · 6 February 2026. In the November 2025 call, management framed the Veterinary API facility as a proactive "strategic entry" and a "launch" to drive long-term growth. However, in the February 2026 call, management admitted this facility was actually a defensive pivot repurposing a unit built for a failed product. Earlier call (Nov 2025): “The launch of our dedicated Veterinary API facility marks our strategic entry into the animal health segment... we see this as just the beginning of a long-term growth opportunity”. Later call (Feb 2026): “To be very candid this is a unit we had actually built for another purpose but that product did not succeed. So we”. Reversal on "One-Off" Expenses · 6 February 2026. Management explicitly characterized increased consulting costs in the November 2025 call as "one-offs" and a limited "three, four-month project." In the February 2026 call, they contradicted this by announcing new assignments and ensuring these costs would continue into the next financial year. Earlier call (Nov 2025): “We have incurred certain costs, which I would call one-offs because it is a consulting firm piece... This is a three, four-month project.” Later call (Feb 2026): “We are also working on another assignment to get AI enablement... this is an investment we will make as we start this current quarter and we head into the next financial year.”

Every quote above is taken word for word from the company’s own earnings calls. ## How much does Sai Life Sciences earn on its capital? Sai Life Sciences Ltd earned a ROCE of 20% in FY26. That is up from a low of 3% in FY22. Its return on capital used (ROIC) is 2.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 15.9% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 15.9% net margin × 0.61× asset turnover × 1.45× leverage (assets divided by equity) ≈ 14.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 14.0% − 12.0% = +2.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 14.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 15.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sai Life Sciences have too much debt? Sai Life Sciences Ltd has total debt of ₹288 Cr against shareholder equity of ₹2,484 Cr as of Jun 2026, so its debt is 0.12× its equity, which is very little. Year by year, that ratio went from 0.95 in FY24 to 0.12 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sai Life Sciences shareholding pattern? Domestic institutions raised their stake in Sai Life Sciences Ltd by 20.4 percentage points over 7 quarters, the biggest change among its owners. Domestic institutions now own 32.3% of the company. Foreign institutions moved +8.2 points over the same period, to 19.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +20.4 points over 7 quarters, to 32.3%; Foreign institutions: +8.2 points over 7 quarters, to 19.9%; Promoters: −0.7 points over 7 quarters, to 34.5%. Why the owners changed: domestic institutions drove it (+20.4 points), together with foreign institutions (+8.2 points). They raised their stake step by step. ## How far is Sai Life Sciences from balance-sheet trouble? For Sai Life Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sai Life Sciences rank in its industry? 57.3 out of 100, rank 10 of 24 in Pharma - API & CRAMS, with 89% of the evidence available. Sai Life Sciences Ltd scores 57.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 10. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 21.7 + 17 + 4.8 + 13.8 = 57.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sai Life Sciences compared with? Sai Life Sciences ranks 10 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 57.3 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. Sai Life Sciences Ltd this page SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Sai Life Sciences in size? Sai Life Sciences is the 5th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Laurus Labs, Gland Pharma and Anthem Biosciences. Just below it: Acutaas Chemicals, Piramal Pharma and Neuland Laboratories. ### Pharma - API & CRAMS companies close in size

1. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) ₹1,29,972 crore
2. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) ₹51,086 crore
3. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ₹46,689 crore
4. Sai Life Sciences Ltd ₹33,093 crore
5. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ₹32,778 crore
6. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) ₹31,807 crore
7. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) ₹25,275 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Blue Star Ltd](https://www.sectoralpha.in/stocks/blue-star-ltd) ₹33,472 crore · Consumer Electronics
2. [Gujarat Gas Ltd](https://www.sectoralpha.in/stocks/gujarat-gas-ltd) ₹33,105 crore · Gas Distribution
3. Sai Life Sciences Ltd ₹33,093 crore
4. [CRISIL Ltd](https://www.sectoralpha.in/stocks/crisil-ltd) ₹33,030 crore · Credit Rating Agencies
5. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ₹32,778 crore · Pharma - API & CRAMS

## What else do people ask about Sai Life Sciences? ### What is Sai Life Sciences's share price today? Sai Life Sciences Ltd's share price is ₹1,546.10, +76.6% over the past year. The whole company is worth ₹32,840 Cr on the market. In the last 52 weeks it traded between ₹795 to ₹1,601; today it is 93% of the way up from the low, 23.3% above its 200-day average (as of 4 November 2026). ### What were Sai Life Sciences's latest quarterly results? Sai Life Sciences Ltd reported revenue of ₹554 Cr and net profit of ₹73.0 Cr for the Jun 2026 quarter. Revenue rose 11.7% and profit rose 21.7% compared with a year earlier. Earnings per share were ₹3.45. The operating margin was 27.0%, 3.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Sai Life Sciences's market cap? Sai Life Sciences Ltd's market capitalisation is ₹32,840 Cr at a share price of ₹1,546.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Sai Life Sciences performing? Sai Life Sciences Ltd's share price has been rising for 70 weeks. In its latest quarter, revenue rose 11.7% and profit rose 21.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 46 weeks running (as of 4 November 2026). ### Will Sai Life Sciences's share price go up? This page does not forecast Sai Life Sciences Ltd's share price. What it shows instead: the share price is ₹1,546.10, and it has been rising for 70 weeks. Its P/E of 89.3× is higher than 77% of its own last 2 years (as of 4 November 2026). ### Who owns Sai Life Sciences? Promoters own 34.5% of Sai Life Sciences Ltd, foreign institutions 19.9%, domestic institutions 32.3% and the public 13.3% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 20.4 percentage points over 7 quarters (as of 4 November 2026). ### Where is Sai Life Sciences in its business cycle? Sai Life Sciences Ltd's FY26 operating margin was 29.0%, against a 8-year range of 14.0% to 29.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 27.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Sai Life Sciences story? The main question: yearly earnings per share moved +102.0% while the share price moved +76.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Sai Life Sciences a stock worth studying right now? What the numbers show: Sai Life Sciences Ltd's earnings have grown faster than its share price. Earnings per share grew +102.0% in a year while the price moved +76.6%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Sai Life Sciences share price forecast for 2026? What management itself guided: Revenue growth of 15-20% over 3-5 years. What is changing at Sai Life Sciences, from the latest results and calls: integrated customer programmes, bidar capacity commissioning and discovery capacity and cro conversion. What would change the story: The thesis breaks if the first Bidar block misses its stated H2 FY27 commissioning window and H2 revenue does not improve despite the added capacity. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.